Evidence map›Paper›PMID 42796754›Full record

SynthesisPathogens (Basel, Switzerland)2026

Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant

Dmitrii N Andreev, Alsu R Khurmatullina, Dmitry S Bordin, Andrey V Zaborovsky, Philipp S Sokolov, Yury A Kucheryavyy, Petr A Beliy, Igor V Maev

Abstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dmitrii N AndreevDepartment of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.ORCID 0000-0002-4007-7112
Alsu R KhurmatullinaDepartment of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.ORCID 0009-0000-4358-7823
Dmitry S BordinDepartment of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.ORCID 0000-0003-2815-3992
Andrey V ZaborovskyDepartment of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia.
Philipp S SokolovDepartment of Pharmacology, Russian University of Medicine, 127473 Moscow, Russia.ORCID 0000-0003-2813-6498
Yury A KucheryavyyIlyinskaya Hospital, 143421 Krasnogorsk, Russia.ORCID 0000-0001-7760-2091
Petr A BeliyDepartment of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.
Igor V MaevDepartment of Internal Disease Propaedeutics and Gastroenterology, Russian University of Medicine, 127473 Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClarithromycin resistance represents the primary obstacle to the success of conventional proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori (

methodsThis systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. The protocol was prospectively registered in PROSPERO (CRD420261407870). A systematic literature search was performed in Embase; MEDLINE/PubMed; CENTRAL; and Web of Science for articles published from 1 February 2015 to 31 March 2026. The included evidence comprised randomized and non-randomized comparative studies, as well as non-comparative studies. The primary outcome was the

resultsA total of 20 unique publications were included; 12 contributed data to the comparative analysis and 9 contributed data to the non-comparative single-arm analysis, with one publication contributing to both analyses. Across the 12 comparative studies, successful eradication was achieved in 464 of 621 patients (74.7%) receiving P-CAB-based regimens and in 301 of 571 patients (52.7%) receiving PPI-based comparators. P-CAB-based regimens were associated with a significantly higher probability of successful eradication compared with PPIs (RR, 1.42; 95% CI, 1.14-1.76;

conclusionsP-CAB-based eradication regimens are significantly more effective than PPI-based comparators in patients with clarithromycin-resistant

Indexed as

Anti-Bacterial AgentsClarithromycinDrug Resistance, BacterialHelicobacter InfectionsHelicobacter pyloriProton Pump InhibitorsDrug Therapy, CombinationHumansTreatment OutcomeAnti-Bacterial AgentsClarithromycinProton Pump Inhibitorsclarithromycin resistanceeradication therapyHelicobacter pylorimeta-analysisP-CABpotassium-competitive acid blockerssystematic reviewtegoprazanvonoprazan

Identifiers

PMID42796754
PMCPMC13610895

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.